Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of oral BCX7353 for hereditary angioedema types I and II
MOH_2018-04-15_002061Phase 2Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of berotralstat in hereditary angioedema (HAE) (2 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Long-term safety. Started Apr 2018; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2018-04-15_002061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-15_002061.